title: Plasmapheresis in severe forms of myasthenia gravis.
abstract: In this study we introduce a new combination treatment of plasma exchange (PE) and high daily doses of prednisone for severe forms of myasthenia gravis (MG). The clinical efficacy of the combined therapy has been tested in 18 patients suffering from severe forms of MG. The protocol included 5 sessions of PE, performed in a range of 15 days, 1 session every 3 days, with concurrent administration of oral prednisone (1 mg/kg of body weight), starting at the first session of PE and given daily for at least 3 months. At the end of the entire cycle of PE, almost complete recovery (more than 90% of the initial clinical score) was obtained in 8 of 18 patients while an improvement between 60 and 90% of the initial score was achieved in 9 of 18 patients. An early improvement was noted 24 h after the beginning of plasmapheresis in 11 of 18 patients. No recurrence of symptoms was reported after 36 months of follow-up for 17 patients. The administration of steroid therapy was never followed by an early exacerbation of myasthenic symptoms as reported when it is administered in the absence of concomitant PE. According to our results, we can conclude that high doses of oral prednisone therapy in simultaneous association with PE lead to successful control of severe forms of MG, significantly superior to the therapeutic strategies until now adopted and reported in literature.
authors.affiliation: Clinica Chirurgica, Università Tor Vergata, Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Morosetti
authors.forename: C
authors.initials: C
authors.lastname: Meloni
authors.forename: C
authors.initials: C
authors.lastname: Iani
authors.forename: M
authors.initials: M
authors.lastname: Caramia
authors.forename: C
authors.initials: C
authors.lastname: Galderisi
authors.forename: G
authors.initials: G
authors.lastname: Palombo
authors.forename: M T
authors.initials: MT
authors.lastname: Gallucci
authors.forename: G
authors.initials: G
authors.lastname: Bernardi
authors.forename: C U
authors.initials: CU
authors.lastname: Casciani
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D010956:Plasmapheresis; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone